Status:
COMPLETED
Muscle Protein Metabolism in Obesity
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Obesity
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Obesity is associated with reduced adenosine triphosphate (ATP) turnover in skeletal muscle, a condition that can impair muscle metabolism. The proposed research will discover mechanisms responsible f...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Body mass index (BMI): lean, 19-26 kg/m2; obese, 30-40 kg/m2
- Availability of transportation
- Ability to sign informed consent form
- Exclusion criteria:
- Medication or supplements (i.e. amino acids, protein) known to affect protein metabolism
- Presence of acute illness
- History of liver disease
- Uncontrolled metabolic disease
- ECG documented abnormalities, atrial fibrillation, history of syncope, limiting or unstable angina, or congestive heart failure
- Chronically elevated blood pressure (systolic, \>140 mmHg; diastolic, \>100 mmHg)
- Cardiac pacemaker or other medical device implanted in the body
- Low hemoglobin or hematocrit
- Current participation in a weight-loss regimen, including extreme dietary practices
- Smoking
- Use of anabolic steroids or corticosteroids (within 3 months)
Exclusion
Key Trial Info
Start Date :
October 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 7 2020
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01824173
Start Date
October 1 2012
End Date
February 7 2020
Last Update
April 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259